Cargando…
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors
High expression levels of human epidermal growth factor receptor 2 (HER2) have been associated with poor prognosis in patients with pancreatic adenocarcinoma (PDAC). However, HER2-targeting immunotherapies have been unsuccessful to date. Here we increase the breadth, potency, and duration of anti-PD...
Autores principales: | Rosewell Shaw, Amanda, Porter, Caroline E., Yip, Tiffany, Mah, Way-Champ, McKenna, Mary K., Dysthe, Matthew, Jung, Youngrock, Parihar, Robin, Brenner, Malcolm K., Suzuki, Masataka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979740/ https://www.ncbi.nlm.nih.gov/pubmed/33742099 http://dx.doi.org/10.1038/s42003-021-01914-8 |
Ejemplares similares
-
Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives
por: McKenna, Mary K., et al.
Publicado: (2020) -
Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
por: Rosewell Shaw, Amanda, et al.
Publicado: (2018) -
Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies
por: Wang, Daniel, et al.
Publicado: (2023) -
Receptor Switching in Newly Evolved Adeno-associated Viruses
por: Havlik, L. Patrick, et al.
Publicado: (2021) -
DNA methylation: potential biomarker in Hepatocellular Carcinoma
por: Mah, Way-Champ, et al.
Publicado: (2014)